Texas 2025 - 89th Regular

Texas House Bill HB855

Voted on by House
 
Out of Senate Committee
 
Voted on by Senate
 
Governor Action
 
Bill Becomes Law
 

Caption

Relating to promoting, prescribing, administering, or dispensing prescription drugs for off-label use.

Impact

This bill protects physicians and pharmacists from punitive actions by state agencies based solely on their decision to prescribe or promote off-label uses of medications. Specifically, it stipulates that regulatory authorities cannot revoke or suspend licenses effectively for these actions unless there is proof that such conduct led to patient harm within a stipulated timeframe. This protection is particularly significant given the evolving landscape of medical practice where new evidence may support innovative uses for existing medications.

Summary

House Bill 855 amends the Health and Safety Code of Texas to address the promotion, prescription, administration, and dispensing of prescription drugs for off-label use. The bill defines 'off-label use' as the application of a medication approved by the FDA for purposes not explicitly authorized. The intent behind this legislation is to provide clarity and protection to healthcare providers when they exercise their professional judgment to prescribe medications for conditions that may not have been included in the drug's original approval.

Contention

Notable points of contention surrounding HB855 include concerns about patient safety and professional standards. Critics may argue that broader allowances for off-label prescriptions could lead to instances of misuse or overreach, potentially putting patients at risk. Proponents emphasize that the bill supports physician autonomy and the ability to make informed decisions for their patients without the fear of retribution for exploring alternative or innovative treatment options.

Implementation

If enacted, the provisions of HB855 would come into effect on September 1, 2025, and apply to all prescriptions issued or drugs promoted, administered, or dispensed after this date. The bill effectively aims to strike a balance between promoting safe healthcare practices while providing necessary legal safeguards for healthcare providers.

Companion Bills

No companion bills found.

Previously Filed As

TX HB4341

Relating to promoting, prescribing, administering, or dispensing prescription drugs for off-label use.

TX SB301

Relating to prescribing, administering, or dispensing ivermectin or hydroxychloroquine sulfate.

TX SB426

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

TX HB972

Relating to warning labels for opioid prescription drugs.

TX HB816

Relating to warning labels for opioid prescription drugs.

TX HB2995

Relating to the prescribing of medical cannabis for medical use to certain veterans with combat-related injuries or medical conditions and the licensing of dispensing organizations under the Texas Compassionate Use Program.

TX SB160

Relating to the furnishing by pharmacists and dispensing by physicians of certain medications.

TX HB2079

Relating to the authority of pharmacists to order and furnish certain prescription drugs.

TX HB343

Relating to the prescriptive authority of certain psychologists; authorizing a fee.

TX HB815

Relating to distinctive packaging for opioid prescription drugs.

Similar Bills

No similar bills found.